Teijin Pharma to Launch Ipsen?s Somatuline Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan
Tokyo, Japan / Paris, France, January 17, 2013 --- Teijin Pharma
Limited, the core company of the Teijin Group’s healthcare
business, and Ipsen (Euronext: IPN; ADR: IPSEY), today announced
the launch of Somatuline® 60/90/120 mg for...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Acromegaly | Pharmaceuticals